Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi

Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a quick raise. The biotech garnered $300 million from the sale of its stock.

Incyte $INCY says its Phase IIb study for a cream formulation of Jakafi (ruxolitinib) produced promising results for patients with atopic dermatitis. Researchers are now moving ahead with a Phase III registration program.

Principia BioPharma is now boosting the size of its proposed IPO. The South San Francisci-based biotech wants to sell 6.3 million shares at a price range of $15 to $17. 

VistaGen Therapeutics $VTGN issued a little more than $2 million in shares to Pheron Pharmaceuticals in exchange for rights to a drug for social anxiety disorder.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->